By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration approved one of its respiratory medicines as a self-administered and pre-filled syringe called the Fasenra pen.

Fasenra, a treatment for severe eosinophilic asthma, can now be used by patients themselves as an injection administered once every eight weeks. The pharmaceutical company said that this allows for more convenient dosing at home.

Fasenra was already approved in the U.S., as well as Europe and Japan as a drug given by doctors.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

October 04, 2019 02:28 ET (06:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.